Study to Test Effects and Safety of RO7568282 In Early Parkinson’s Disease

Other illness

• Medical history indicating a parkinsonian syndrome other than idiopathic Parkinson’s disease
• Diagnosis of Parkinson’s Disease dementia
• Diagnosis of a significant neurologic disease other than Parkinson’s Disease
• Within the last year, unstable or clinically significant cardiovascular disease
• Chronic uncontrolled hypertension
• History or presence of brain MRI scan showing evidence of structural abnormalities, other than related to Parkinson’s disease

• Diagnosis of idiopathic Parkinson’s disease
• Has received stable doses of monotherapy treatment with levodopa for at least 2 months prior to baseline
• A Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV score of 0 at screening and prior to randomization at baseline
• Hoehn and Yahr (H&Y) Stage ≤ 3 (assessed in off medication state) at screening and prior to randomization at baseline
• Able to swallow whole capsules
• Participants must be aged 40 to 85 years, inclusive, at the time of signing the Informed Consent Form